Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens | Zendy

Sam Afkhami | Zendy; Yushi Yao | Zendy; Zhou Xing | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens

Author(s) -

Sam Afkhami,

Yushi Yao,

Zhou Xing

Publication year - 2016

Publication title -

molecular therapy — methods and clinical development

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.285

H-Index - 32

ISSN - 2329-0501

DOI - 10.1038/mtm.2016.30

Subject(s) - virology , viral vector , vaccination , immunization , vector (molecular biology) , tuberculosis vaccines , vaccinia , biology , mycobacterium tuberculosis , immunology , medicine , immune system , tuberculosis , recombinant dna , biochemistry , pathology , gene

Adenoviruses represent the most widely used viral-vectored platform for vaccine design, showing a great potential in the fight against intracellular infectious diseases to which either there is a lack of effective vaccines or the traditional vaccination strategy is suboptimal. The extensive understanding of the molecular biology of adenoviruses has made the new technologies and reagents available to efficient generation of adenoviral-vectored vaccines for both preclinical and clinical evaluation. The novel adenoviral vectors including nonhuman adenoviral vectors have emerged to be the further improved vectors for vaccine design. In this review, we discuss the latest adenoviral technologies and their utilization in vaccine development. We particularly focus on the application of adenoviral-vectored vaccines in mucosal immunization strategies against mucosal pathogens including Mycobacterium tuberculosis, flu virus, and human immunodeficiency virus

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research